All news

Barclays lifts AbbVie target to $335, keeps Overweight

Alpha Vantage · TIKR.com · · AI-summarised by FinFlash

Barclays raised its AbbVie price target to $335 from $325 and maintained an Overweight rating, after the stock gained 27% over the past year. The call follows strong third-quarter results driven by Skyrizi and Rinvoq revenue growth and raised 2026 earnings guidance. Barclays' target implies a 21x forward earnings multiple, above AbbVie's five-year peak.

Read original source

ABBV company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.